LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

13.76 -1.01

Buy Sell

Overview

Share price change

24h

Current

Min

13.43

Max

13.92

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.389 57.833
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+42.05% upside

Market Stats
By TradingEconomics
Market Cap	2.6B
Previous open	14.77
Previous close	13.76

News Sentiment

By Acuity

50%

171 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 mar 2026, 18:34 UTC

Earnings

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19 mar 2026, 17:43 UTC

Major Market Movers

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19 mar 2026, 23:39 UTC

Earnings

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19 mar 2026, 23:39 UTC

Earnings

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19 mar 2026, 23:39 UTC

Earnings

Li Ning: Outdoor Category Continued Growing >2331.HK

19 mar 2026, 23:38 UTC

Earnings

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19 mar 2026, 23:33 UTC

Market Talk

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

McCormick Has a Market Value of Around $14.8B -- WSJ

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19 mar 2026, 22:23 UTC

Market Talk

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19 mar 2026, 22:09 UTC

Market Talk

Major News Events

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19 mar 2026, 22:06 UTC

Market Talk

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19 mar 2026, 22:04 UTC

Earnings

Acquisitions, Mergers, Takeovers

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19 mar 2026, 22:03 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

19 mar 2026, 22:03 UTC

Market Talk

Major News Events

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19 mar 2026, 21:51 UTC

Earnings

Acquisitions, Mergers, Takeovers

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19 mar 2026, 20:57 UTC

Major News Events

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

19 mar 2026, 20:19 UTC

Major News Events

Brent Crude Retreats After Touching $119 -- WSJ

19 mar 2026, 19:49 UTC

Market Talk

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19 mar 2026, 19:26 UTC

Major News Events

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19 mar 2026, 19:10 UTC

Market Talk

Major News Events

Natural Gas Rises in Volatile Trading -- Market Talk

19 mar 2026, 19:06 UTC

Major News Events

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19 mar 2026, 18:08 UTC

Market Talk

Major News Events

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

42.05% upside

12 Months Forecast

Average 20 USD 42.05%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

171 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.